SCHEMBL14744889

SCHEMBL14744889

CCCC(O)c1ccc2c(ccn2C)c1OCc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
GLRA1 P23415 2/20 0.34
TP53 P04637 2/20 0.34
GAA P10253 2/20 0.34
THRB P10828 1/20 0.34
IDO1 P14902 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HTT P42858 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HPGD P15428 2/20 0.33
SRD5A2 P31213 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
BRD4 O60885 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9315204 0.78 HTR1A (0.43) MAPTTP53GAATHRBMEN1
SCHEMBL8913156 0.76 MEN1 (0.42) MAPTGAAMEN1KMT2AALDH1A1
SCHEMBL28151566 0.76 MEN1 (0.42) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL14745954 0.75 LMNA (0.40) MAPTTHRBMEN1KMT2AALDH1A1
SCHEMBL14745549 0.75 KDM4E (0.38) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL13570132 0.74 MAPT (0.47) MAPTGAAMEN1KMT2AALDH1A1
SCHEMBL27972960 0.74 MTNR1A (0.54) MEN1KMT2AALDH1A1LMNA
SCHEMBL14745052 0.72 NPC1 (0.44) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL14744993 0.71 LMNA (0.49) MAPTGAAMEN1KMT2AALDH1A1
SCHEMBL14745011 0.71 TSHR (0.33) MAPTMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP MAPT 4110/4885GLRA1 3356/4885TP53 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.